Three-year data highlights inflammation control in psoriatic arthritis
Category: News
Rheumatology studies show promising results for Sjogren’s disease
Biotech firm to collaborate with NHS on early detection study
Therapy indicated for children aged 3 to 14 at treatment initiation
New funding supports development of diagnostic platform
Treatment provides option for children with growth failure
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
New guidance expands treatment options for eligible patients
Updated guidance from NICE expands eligibility for dapagliflozin us
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise